| Title | Profile of long-acting reversible contraception users in Europe. | | Author(s) | Haimovich S | | Institution | Department of Obstetrics and Gynaecology, Del Mar University Hospital IMAS, Paseo Maritimo 25-29, Barcelona 08003, Spain. sergio@haimovich.net | | Source | Eur J Contracept Reprod Health Care 2009 Jun; 14(3):187-95. | | MeSH | Adolescent
Adult
Age Distribution
Computers
Condoms
Contraception Behavior
Contraceptive Agents, Female
Contraceptive Devices
Contraceptive Devices, Female
Drug Implants
Europe
Female
Humans
Interviews as Topic
Intrauterine Devices, Copper
Levonorgestrel
Middle Aged
Patient Satisfaction
Young Adult
| | Abstract | OBJECTIVES: To assess the profile of long-acting reversible contraceptives (LARCs) users in Europe.
METHODS: A random sample of women aged 15-49 years in 14 European countries (Germany, France, UK, Spain, Italy, Russian Federation, Estonia, Latvia, Lithuania, Austria, Czech Republic, Denmark, Norway, and Sweden) underwent web-based or computer-aided face-to-face interviews in June 2006. In this paper data pertaining to a subgroup of women using LARCs are presented.
RESULTS: A total of 11,490 women participated in the full study. Of these, 1,188 (10%) women were LARC (hormonal implant, injectables, levonorgestrel-releasing intrauterine system [LNG-IUS], copper intrauterine device [Cu-IUD]) users. The age of the LARC users exceeded 30 years for 57-91% of them. Furthermore, more than half of them found convenience an extremely important factor when selecting the LARC as a contraceptive method. As compared to those wearing a Cu-IUD, women using hormonal LARCs experienced fewer physical and emotional symptoms that appeared or worsened during menstruation.
CONCLUSIONS: LARCs have their place in the contraceptive market in Europe. The most popular LARCs among European women were the LNG-IUS and the Cu-IUD; both were mainly used by women who had children and had no wish to have more in the future. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
| | PubMed ID | 19565416 |
|
